Kornimate/medical-research-clean huggingface dataset:
prevalence of hbv in pregnancy

Conditions: Hepatitis B

Summary: the most common mode of hbv transmission is materno-fetal transmission mainly during labor. this study aims to estimate the seroprevalence of hbv infection and the possible risk factors of hbv acquisition in pregnant women in upper egypt and to evaluate the predictive value of hbeag and quantitative hbsag as surrogate markers for high viremia in pregnant women.

hepatitis b virus (hbv) is a cause of a vaccine-preventable life-threatening infection of the liver. worldwide, the estimated number of cases of chronic hbv infection is 296 million cases with about 820 000 deaths, mostly due to liver cirrhosis and hepatocellular carcinoma. the prevalence of hbv infection among pregnant women is estimated to be 1.5-9.5%. the most important risk factor of materno-fetal transmission is high viremia. other factors include hepatitis b e antigen (hbeag) seropositivity, hbv s variant, and threatened preterm labor. quantitative hepatitis b surface antigen (hbsag) was postulated as a surrogate marker for hbv high viremia in pregnant women by many authors. this study aims to estimate the seroprevalence of hbv infection and the possible risk factors of hbv acquisition in pregnant women in upper egypt and to evaluate the predictive value of hbeag and quantitative hbsag as surrogate markers for high viremia in pregnant women.

Eligibility criteria:
inclusion criteria: * all pregnant women exclusion criteria: -

Keywords: hepatitis b pregnancy prevalence
efficacy of visual screening in ontario

Conditions: Amblyopia

Summary: amblyopia (lazy eye), is the leading treatable cause of vision loss in childhood. uncorrected refractive errors (ie farsightedness) can lead to difficulties in school. unfortunately, many children do not receive vision screening until they have already developed irreversible vision problems. we will conduct a cluster randomized clinical trial in which schools, not individual children, are randomly allocated to receive a kindergarten visual screening program or to receive no intervention by the research team (i.e., "care as usual"). we will compare the prevalence of visual problems (and proportion of children with reading problems) when the children are in grade 2, after allowing for at least one year of treatment.

the proposed study is a single-masked cluster randomized clinical trial, with randomization and analyses occurring at the level of "schools" (i.e., we are not randomly assigning individuals to groups). to assess the efficacy of a visual screening program, we will compare visual outcomes in 25 schools randomly chosen to receive the program and 25 schools allocated to "care as usual" one year after screening. the screening tools are hotv crowded acuity, preschool randot stereoacuity test, and plusoptix autorefractor. the outcome measures will assess later differences between schools receiving the visual screening program and control schools for prevalence of (1) visual and (2) reading problems. a lower prevalence of either or both problems in schools where the visual screening program was offered would provide evidence for the efficacy of vision screening. primary outcome measure is the prevalence of amblyopia, reduced stereo vision, and untreated clinically significant refractive errors in "screened" versus "care as usual" schools. secondary outcome measure is the proportion of children performing 1 standard deviation below average on reading scores in "screened" versus "care as usual" schools.

Eligibility criteria:
inclusion criteria: * screening: children enrolled in senior kindergarten (age 5-6 years) * follow-up: children enrolled in grade 2 (age 7-8 years) exclusion criteria: • none
sandostatin lar® depot in patients with primary insulin hypersecretion (pih) and at least moderate obesity

Conditions: Primary Insulin Hypersecretion; Obesity

Summary: this study is in patients with at least moderate obesity (body mass index \[bmi\] \> 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). sandostatin lar® depot suppresses insulin, and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin. the main purpose of the study is to find the lowest dose of sandostatin lar® depot that safely helps overweight people lose weight. the study will also compare weight loss in obese patients who receive one of three different dosages of sandostatin lar depot or placebo.


Eligibility criteria:
inclusion criteria: you may qualify for this study if you: * are between the ages of 18-70 (male or female) * are at least moderately obese (bmi \> 30 kg/m2 or approximately 30 or more pounds overweight) * and pass an oral glucose tolerance test (a 3 hour test to determine if your body produces too much insulin) exclusion criteria: you are not qualified for this study if you: * have diabetes * have been able to lose weight with diet and exercise alone * have previously received sandostatin lar® depot

Keywords: primary insulin hypersecretion pih obesity
administration of allogenic red blood cells loaded l-asparaginase in cases of relapse of acute lymphoblastic leukaemia

Conditions: Acute Lymphoblastic Leukemia

Summary: primary objective : * to explore the relation between 3 doses of graspa and duration of asparagine depletion (\< 2µmol/l) secondary objective : * pharmacokinetic / pharmacodynamic parameters * toxicity * study duration : 2 years * study treatment : red blood cells loaded with l asparaginase versus native l asparaginase * associated treatments : coprall chemotherapy * randomization : centralised randomisation on scratching list


Eligibility criteria:
inclusion criteria: * subject between 1 and 55 year old * subject with acute lymphoblastic leukaemia or lymphoblastic lymphoma (excluded burkitt lymphoma) who have relapsed after first remission (medullary or snc relapse) * or patient who still refractory to first line chemotherapy for an all * patient who gave written informed consent (2 parents for children) exclusion criteria:

Keywords: relapse lymphoma lymphoblastic
safety and effectiveness of abt-510 plus combination chemotherapy in subjects with non-small cell lung cancer (nsclc)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the primary objective of this phase ii study is to assess the safety, pharmacokinetics and effectiveness of abt-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage iiib or iv nsclc.


Eligibility criteria:
inclusion criteria * the subject is at least 18 years of age. * the subject has histologically or cytology documented stage iiib with pleural effusion or stage iv nsclc. the subject must have measurable disease (recist criteria for tumor response). * the subject has not received first line therapy for treatment of nsclc. * the subject must not be pregnant or lactating and all subjects (male and female) must use a contraceptive method deemed acceptable by the investigator while in the study and for up to two months following completion of therapy. * the subject has an eastern cooperative oncology group (ecog) performance score of 0-1. * the subject is able to self-administer or has a caregiver who can reliably administer sc injections. * the subject must have adequate bone marrow, renal and hepatic function as follows: * bone marrow: white blood cell count (wbc) \>= 3,000/mm3; platelets; \>= 100,000/mm3; hemoglobin \>= 9.0 g/dl; * renal function: serum creatinine \<= 2.0 mg/dl; * hepatic function: bilirubin \<= 1.5 mg/dl; ast and alt \<= 1.5 x the upper normal limit (uln); unless liver metastases are present, then ast and alt \<= 5.0 x uln. * the subject has voluntarily signed and dated an institutional review board (irb)/independent ethics committee (iec) approved consent prior to any study specific procedures. exclusion criteria * the subject has a history of or currently exhibits central nervous system (cns) metastasis. brain mri within 28 days of enrollment is required to confirm absence of cns metastases. * the subject is receiving therapeutic anticoagulation therapy. low dose anticoagulation for catheter prophylaxis will be permitted; pt/ptt must be within normal limits. * the subject has a history of or currently exhibits clinically significant cancer related events of bleeding (e.g., hemoptysis). the subject has a recent history of (within 4 weeks from study day 1) or currently exhibits other clinically significant events of bleeding. * the subject has received investigational therapy within four weeks prior to study drug administration. * the subject exhibits evidence of clinically significant uncontrolled condition(s) and/or is considered by the investigator to be unable to tolerate the proposed treatment or procedures. * the subject has previous or current malignancies at other sites, with the exception of: adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin; previous nonpulmonary malignancy confined and surgically resected with no evidence of active malignancy.

Keywords: stage iiib with pleural effusion or iv nsclc
psychometric measurement properties of the michigan hand questionnaire in patients after flexor tendon repair

Conditions: Flexor Tendon Rupture

Summary: the aim of the study is to investigate the psychometric properties of the german version of the michigan hand questionnaire in patients with flexor tendon injuries, including reliability, validity and interpretability.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * ≥ 18 years old * understanding of the german language (written and oral) * single and multiple finger injuries * primary flexor tendon injuries in zone i-v for the fingers and/ or thumb * treated by the hand surgery department at the inselspital bern * treated with at least a 4-strand core suture exclusion criteria: * \< 18 years old * inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients * replantation of the injured finger * fracture of the injured finger * primary tendon reconstructions
sacral erector spinae plane blocks in pediatric patients

Conditions: Postoperative Pain

Summary: patients who were operated by department of pediatric surgery and who received sacral erector spinae plane blocks as a part of postoperative analgesia management will be scanned.

erector spinae plane block (espb) is a safe and effective regional anesthesia technique in pediatric patients and can be performed at any level of the thoracic and lumbar vertebrae. in addition, espb can be performed at the sacral region in the midline. in pediatric patients, sacral espb provides effective analgesia and this method can replace caudal blocks. this study aims to investigate the efficacy of sacral espb retrospectively. demographical data of the patient, indication/surgery type, total volume applied, additional analgesic use, type of the analgesic if used will be investigated.

Eligibility criteria:
inclusion criteria: * patients who were operated by department of pediatric surgery exclusion criteria: * incomplete patient forms
d2 dopamine receptor on human aldosterone-producing adenoma and its role in aldosterone secretion and cell proliferation

Conditions: Hypertension; Adrenal Aldosterone-Producing Adenoma

Summary: dopamine (da) is one of the main catecholamines in mammals. its major role as a brain neurotransmitter is well known as well as its contribution to the development of pathologies, mainly arterial hypertension. traditionally, dopamine receptors are divided into two families according to the stimulation or inhibition they may produce at the adenyl cyclase level. five dopamine receptors have been identified: d1 (d1a) and d5 (d1b) exist in the d1 family. d2s, d2l, d3 and d4 belong to the d2 family. formerly, less than 1% of patients with hypertension were believed to have primary hyperaldosteronism; however, recent studies have suggested that primary aldosteronism affects 5-13% of patients with hypertension and aldosteronomas are a more common cause of hypertension than previously thought. at least 2% of patients with hypertension may have an aldosteronoma. the investigators' previous clinical observation found two subtypes of aldosterone-producing adenoma (apa), which were defined according to their responses to metoclopramide during salt manipulation. on a high-salt diet (hs), the nonsuppressible subjects, with less dopaminergic inhibition of aldosterone secretion, had less urinary da excretion and greater blood pressure (bp) elevation \[wu kd et al. 2002\]. the investigators' recent study of six patients with an apa found that the expression of the d2 receptor in apa was not universal. the amounts of d2 receptor messenger ribonucleic acid (mrna) were more variant in either apa or their remnant adrenal glands. only two cases of apa expressed the d2 receptors with much weaker signals compared with those in their respective remnant adrenals \[wu kd et al. 2001\]. the investigators' current work demonstrates that the d2 receptor negatively regulates aii-stimulated aldosterone secretion and aldosterone synthase mrna expression in nci-h295r cells. on the other hand, the d4 receptor counteracts with the effect of the d2 receptor. in a future study, the investigators wish to quantify d2 and d4 receptor mrna and protein expression in apa and their remnant adrenal glands and correlate them to their clinical metoclopramide test results. the investigators also wish to know whether the difference between the d2 and d4 receptor expression reflect the different effects of dopamine inhibition on aii-stimulated aldosterone secretion and aldosterone synthase transcription. finally, the investigators will explore the role of d2 and d4 receptors on aii-stimulated adrenal cell proliferation.


Eligibility criteria:
inclusion criteria: * adrenal aldosterone-producing adenoma

Keywords: normal part of the adrenal gland
heftme system for adjuvant therapeutic selection of locally advanced utuc postoperatively：a perspective cohort study

Conditions: Upper Tract Urothelial Carcinoma

Summary: this multicenter, real-world study introduces a novel hematoxylin-eosin staining(h\&e)-based four tumor microenvironment (tme) system (heftme system) assisting in prognostic prediction and precise adjuvant treatment selection for lautuc postoperatively.


Eligibility criteria:
inclusion criteria: * pathological diagnose of utuc; * met more than muscle-invasion stages(pt2+) or lymph nodes metastasis. exclusion criteria: * patients with early-local stages (pta/t1/tis) without lnm+ and those with incomplete pathologic and prognostic information were excluded

Keywords: he-stained slides tumor microenvironment precise subtype adjuvant therapy
sitagliptin for the treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes

Conditions: Type 2 Diabetes; Nonalcoholic Steatohepatitis

Summary: this is a randomized, double-blind, placebo-controlled trial evaluating the impact of sitagliptin therapy in patients with concomitant type 2 diabetes and non-alcoholic steatohepatitis (nash) on improving liver disease based on biopsy results. the effect of sitagliptin on other measures such as hormones modifying insulin release and sensitivity (termed adipocytokines), fat distribution, and biomarkers of cardiovascular risk will also be evaluated.


Eligibility criteria:
inclusion criteria: * known dm2 (receiving lifestyle management and/or metformin and/or sulfonylurea * stable therapy for dm2 for the past 3 months * all other medications and doses stable for past 3 months * hba1c 8.9% or lower (can be done in past 30 days) * known nash based on the accepted american gastroenterological association criteria: 1. alcohol consumption (\< 10g/day in women and \<20g/day in men) 2. cause of liver disease other than nafld (negative investigations for: viral hepatitis, iron overload, a-1 antitrypsin, ceruloplasmin, autoimmune disease) 3. liver histology demonstrating macrovesicular fatty change of hepatocytes, with evidence of steatohepatitis, manifested by the presence of mallory bodies, ballooning degeneration, lobular neutrophilic inflammation and perisinusoidal fibrosis. (if liver biopsy done within 2 years prior to screening for this trial, that biopsy will be reviewed to ensure it meets criteria for diagnosis). exclusion criteria: * any contraindication for undergoing mri * child class b or c cirrhosis * participation in another clinical trial * use of thiazoledinedione (rosiglitazone or pioglitazone) in past 6 months * current use of plavix * previous exposure to sitagliptin * prior history of pancreatitis * history of anaphylaxis to another canadian-marketed dpp-iv inhibitor (saxagliptin) * creatine clearance \<30 ml/min * anaemia (haemoglobin \< 110 mg/dl) * platelet count \< 50 000 cells/mm3 * known heart or kidney failure * comorbid condition that decreases natural life span (e.g. known cancer) * pregnant or breastfeeding or wishing to become pregnant in the next 6 months * current or past treatment with medications that can induce steatohepatitis (e.g. glucocorticoids, methotrexate, amiodarone etc.)
knowledge, beliefs and attitudes of greek physiotherapists about communication with chronic musculoskeletal patients

Conditions: Musculoskeletal Pain; Chronic Pain

Summary: the purpose of current research study is to assess physiotherapists's knowledge, beliefs and attitudes about empathy, motivational interviewing and shared decision making in chronic musculoskeletal patients. an e-survey study will be conducted based on checklist for reporting results of 52 internet e-surveys (cherries)

the main questions it aims to answer are: what physiotherapists know about the use of empathy, motivational interviewing and shared decision making? what beliefs do physiotherapists have about the appropriate use of communication skills? whether and how much they use empathy, motivational interview, shared decision-making in clinical practice? what are the main barriers of using communication skills (empathy, motivational interview, joint decision-making) in clinical practice?

Eligibility criteria:
inclusion criteria: * physiotherapists who are member of panhellenic association of physiotherapist in greece, with active clinical practice in greece and clinical experience in musculoskeletal disorders (\>12 months). exclusion criteria: * none

Keywords: empathy shared decision making motivational interviewing physiotherapy chronic musculoskeletal patients
heart health 4 new moms: a randomized trial in the first year after preeclampsia

Conditions: Preeclampsia; Gestational Hypertension; Hypertension; Obesity; Overweight and Obesity; Pregnancy Complications; Pregnancy Toxemia; Postpartum Preeclampsia

Summary: preeclampsia causes devastating maternal and neonatal morbidity and mortality with a high recurrence risk and a rapid, occult progression to cardiovascular disease after delivery. there is a critical need for effective interventions to reduce these risks. this is a pilot randomized controlled trial of a novel postpartum lifestyle intervention compared to women who take home blood pressure measurements and women with usual care who are overweight and obese in the first year after preeclampsia. the investigators hypothesize that the intervention will lead to improved weight loss and blood pressure in the first year postpartum, which has broad implications for future pregnancy and long-term cardiovascular health.

the overall objective of this study is to conduct a pilot trial of an internet-based lifestyle intervention and home blood pressure monitoring in the year after delivery among overweight and obese women with preeclampsia to evaluate feasibility, acceptability and to assess the effect of the intervention. the investigators hypothesize that compared to usual care, an internet-based lifestyle intervention implemented in the immediate postpartum period in overweight and obese women with preeclampsia improves weight loss at one year postpartum. 150 overweight or obese women with preeclampsia will be randomized into internet-based lifestyle intervention plus home blood pressure monitoring, home blood pressure monitoring alone, or usual care groups in the postpartum period. the investigators will assess feasibility by the proportions of women who are eligible, enroll, and remain in the study at one year. the effect of home blood pressure monitoring on blood pressure and progression to sustained hypertension will also be explored. a successful outcome of this study would have a direct impact to improve cardiovascular health and future pregnancy health in women who have had preeclampsia.

Eligibility criteria:
inclusion criteria: * pre-pregnancy body mass index ≥25 kg/m2 * diagnosed with preeclampsia or gestational hypertension * access to internet exclusion criteria: * multiple gestation * medical co-morbidities: chronic kidney disease, active liver disease (acute hepatitis, chronic active hepatitis), active cardiac disease, pre-pregnancy diabetes mellitus, chronic hypertension diagnosed prior to pregnancy * pregnancy prior to randomization
efficacy of the atp switch automatic programming in implantable cardioverter defibrillator (icd) and cardiac resynchronization therapy defibrillator (crt-d) implanted patients

Conditions: Ventricular Arrythmias

Summary: primary objective is to assess the efficacy of the new atp autoswitch function in simple, dual or triple chamber icd.

the efficacy rate of the atp auto-switch function, defined as the % of vt episodes successfully reduced, will be compared with 85%.

Eligibility criteria:
inclusion criteria: * the patient has been implanted (primo implantation or replacement) with an icd model paradym vr 8250, dr 8550, crt 8750, crt 8770 models or any similar or higher range device * atp auto-switch function is programmed on exclusion criteria: * presence of a contra-indication to the icd therapy * life expectancy less than 12 months

Keywords: atp,crt, icd paradym
prospective post-market evaluation of an echogenic catheter

Conditions: Peripheral Nerve Block Procedure

Summary: patients scheduled for mastectomy and suitable for paravertebral block will be randomized to one of 2 groups. group 1 will have the nerve block performed using a standard non-echogenic needle and catheter under ultrasound guidance. group 2 will have the block performed using the control needle and an echogenic catheter, all under ultrasound (us) guidance. the clinician will be blinded to the catheter type and will assess the quality of catheter visualisation of the us image during the procedure, along with adequacy of spread of local anesthetic. the primary outcome will be needle visibility, and secondary outcomes will be block success rate and block quality. an assessment of the patient's pain levels after the procedure will also be conducted.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo breast surgery requiring use of a peripheral nerve block catheter for establishing a paravertebral block * patients classified as asa (american society of anesthesiologists) physical status i, ii or iii * patients at least 18 years old * patient is willing and able to provide informed consent for study participation * patient has a good understanding of written and verbal english exclusion criteria: * patient with contraindications to regional anesthesia technique (e.g. allergy to local anesthetic or other medications used in study) * patient with known coagulopathy * patient whose target nerve cannot be seen with linear ultrasound probe in a pre-procedure scan. all patients who need a curvilinear probe to visualize the target nerve will be excluded from the study. * patients having mastectomy and immediate reconstruction

Keywords: paravertebral block mastectomy post-operative pain echogenic peripheral nerve block catheter